These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

177 related items for PubMed ID: 8851609

  • 1. Susceptibilities of non-Pseudomonas aeruginosa gram-negative nonfermentative rods to ciprofloxacin, ofloxacin, levofloxacin, D-ofloxacin, sparfloxacin, ceftazidime, piperacillin, piperacillin-tazobactam, trimethoprim-sulfamethoxazole, and imipenem.
    Spangler SK, Visalli MA, Jacobs MR, Appelbaum PC.
    Antimicrob Agents Chemother; 1996 Mar; 40(3):772-5. PubMed ID: 8851609
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Antimicrobial activity of 12 broad-spectrum agents tested against 270 nosocomial blood stream infection isolates caused by non-enteric gram-negative bacilli: occurrence of resistance, molecular epidemiology, and screening for metallo-enzymes.
    Jones RN, Pfaller MA, Marshall SA, Hollis RJ, Wilke WW.
    Diagn Microbiol Infect Dis; 1997 Nov; 29(3):187-92. PubMed ID: 9401811
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Comparison of the bactericidal activities of ofloxacin and ciprofloxacin alone and in combination with ceftazidime and piperacillin against clinical strains of Pseudomonas aeruginosa.
    Klepser ME, Patel KB, Nicolau DP, Quintiliani R, Nightingale CH.
    Antimicrob Agents Chemother; 1995 Nov; 39(11):2503-10. PubMed ID: 8585734
    [Abstract] [Full Text] [Related]

  • 10. Comparative in-vitro activities of trovafloxacin, ciproflaxacin, ofloxacin, and broad-spectrum beta-lactams against aerobe blood culture isolates.
    Seifert H.
    Zentralbl Bakteriol; 1998 Dec; 288(4):509-18. PubMed ID: 9987189
    [Abstract] [Full Text] [Related]

  • 11. [Surveillance of antimicrobial resistance among nosocomial gram-negative pathogens from 15 teaching hospitals in China in 2005].
    Yang QW, Xu YC, Chen MJ, Hu YJ, Ni YX, Sun JY, Yu YS, Kong HS, He L, Wu WY, Ye HF, Yang YM, Zhu LN, Guo SH, Ji P, Zhu ZH, Ren JK, Zhang LX, Sun ZY, Zhu XH, Tong MQ, Zhao WS, Mei YN, Liu Y, Zhang ZJ, Duan Q, Li D, Liu PP, Wang J, Han LX, Wang H, Xie XL.
    Zhonghua Yi Xue Za Zhi; 2007 Oct 23; 87(39):2753-8. PubMed ID: 18167265
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. In vitro activity of ceftazidime, cefotaxime and piperacillin against multi-resistant gram-negative bacteria tested with a modified agar dilution method.
    Hoogkamp-Korstanje JA, Meijer CA.
    Eur J Clin Microbiol; 1982 Jun 23; 1(3):166-70. PubMed ID: 6293813
    [Abstract] [Full Text] [Related]

  • 14. Comparative in vitro activity of Meropenem, Imipenem and Piperacillin/tazobactam against 1071 clinical isolates using 2 different methods: a French multicentre study.
    Joly-Guillou ML, Kempf M, Cavallo JD, Chomarat M, Dubreuil L, Maugein J, Muller-Serieys C, Roussel-Delvallez M.
    BMC Infect Dis; 2010 Mar 18; 10():72. PubMed ID: 20298555
    [Abstract] [Full Text] [Related]

  • 15. Comparative in vitro activity of sulfametrole/trimethoprim and sulfamethoxazole/trimethoprim and other agents against multiresistant Gram-negative bacteria.
    Livermore DM, Mushtaq S, Warner M, Woodford N.
    J Antimicrob Chemother; 2014 Apr 18; 69(4):1050-6. PubMed ID: 24257317
    [Abstract] [Full Text] [Related]

  • 16. In vitro synergy testing of levofloxacin, ofloxacin, and ciprofloxacin in combination with aztreonam, ceftazidime, or piperacillin against Pseudomonas aeruginosa.
    Pendland SL, Messick CR, Jung R.
    Diagn Microbiol Infect Dis; 2002 Jan 18; 42(1):75-8. PubMed ID: 11821176
    [Abstract] [Full Text] [Related]

  • 17. Activity of piperacillin/tazobactam in combination with amikacin, ciprofloxacin, and trovafloxacin against Pseudomonas aeruginosa by time-kill.
    Burgess DS, Hastings RW.
    Diagn Microbiol Infect Dis; 2000 Sep 18; 38(1):37-41. PubMed ID: 11025182
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. [Analysis of the distribution characteristics and drug resistance of non-fermenting bacterial infection in intensive care unit from 2009 to 2015].
    Hao D, Hu Z, Liu X, Sun T, Wang T, Tian H, Wang X.
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2016 May 18; 28(5):439-44. PubMed ID: 29920041
    [Abstract] [Full Text] [Related]

  • 20. Ceftolozane/tazobactam activity tested against Gram-negative bacterial isolates from hospitalised patients with pneumonia in US and European medical centres (2012).
    Farrell DJ, Sader HS, Flamm RK, Jones RN.
    Int J Antimicrob Agents; 2014 Jun 18; 43(6):533-9. PubMed ID: 24856078
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.